New Blood Thinner Study May Change Conversations After a Dangerous Clot
A new trial found less clinically important bleeding with apixaban than rivaroxaban after a serious clot, but treatment changes still need a clinician.
Prescriptions
-
-
Dry Mouth From Common Medications Can Raise Cavity Risk: What Adults Should Watch For
Dry mouth is more than a nuisance. Many common medicines can reduce saliva, which can raise cavity risk and make it harder to protect teeth.
-
What the latest pain guidance means for people with arthritis
Current U.S. pain guidance says arthritis care should usually start with non-opioid options, with treatment tailored to arthritis type and daily function.
-
ADHD Medications and Telehealth in 2026: What the Federal Extension Means for Patients
Federal telehealth prescribing flexibility for ADHD stimulants continues through December 31, 2026. Here’s what changed, what did not, and where barriers remain.
-
Drug Safety & Recalls | Drug Safety, Shortages & Recalls | Healthcare Policy & Access | Prescriptions
FDA’s compounded GLP-1 crackdown: What changed after Ozempic, Wegovy, Mounjaro, and Zepbound shortages ended
With semaglutide and tirzepatide shortages resolved, the FDA is tightening scrutiny of mass-marketed compounded GLP-1s. Here is what changed and what patients should ask now.
-
Will Medicare make Ozempic and Rybelsus cheaper? What people with diabetes should know now
The short answer is not yet. Medicare has selected Ozempic, Rybelsus, and Wegovy for drug price negotiation, but the negotiated Medicare price is not scheduled to begin until January 1, 2027. Here is what changed in 2026, why the timeline is confusing, and why your own costs can still vary by plan.
-
First Generic Flovent HFA Approved: What People With Asthma Should Know About Cost, Coverage, and Daily Control
The FDA has approved the first generic of Flovent HFA, but this is not a simple fix for every family affected by the brand-name inhaler’s discontinuation. Here’s what changed, who it may help, and why coverage and pharmacy access may still be uneven.
-
Medicare Price Talks Are Moving Toward More Arthritis Drugs: What Patients Taking Xeljanz, Orencia, Cosentyx, or Cimzia Should Know
As of April 2, 2026, nothing changes at the pharmacy yet for Medicare patients taking Xeljanz, Orencia, Cosentyx, or Cimzia. What changed is that Medicare has selected these drugs for its third negotiation cycle, manufacturers are participating, and any negotiated prices would not begin until January 1, 2028.
-
A New Oral Gonorrhea Drug Won FDA Approval. What the Zoliflodacin Trial Actually Found
The FDA has approved Nuzolvence, an oral form of zoliflodacin, for some uncomplicated gonorrhea cases. Here is what the phase 3 trial found, what noninferior means, and why this does not apply to every gonorrhea infection.
-
Medicare Drug Price Negotiations in 2026: What the New Prices Mean for Patients
In 2026, Medicare beneficiaries are seeing the first real-world effects of negotiated drug prices and a new $2,000 annual out-of-pocket cap under Part D. Here’s what changed, which drugs are affected, and what to check with your plan.
-
How Medicare Drug Price Negotiation Is Changing What Seniors Pay in 2026
In 2026, the first negotiated drug prices under Medicare’s new program take effect. Here’s what that means for seniors, how the Maximum Fair Price works, and how the $2,000 Part D cap fits in.
-
Drug Safety & Recalls | Drug Safety, Shortages & Recalls | Healthcare Policy & Access | Prescriptions
U.S. Drug Shortages in 2026: What the FDA List Means for Patients and How to Protect Your Care
Drug shortages remain a nationwide issue in early 2026. Here’s what it means when a medication appears on the FDA’s Drug Shortages list, how shortages differ from recalls, and what patients should do to protect their care.
-
ADHD and Telehealth in 2026: What the Extended Federal Prescribing Flexibilities Mean for Patients
Federal agencies extended pandemic-era telehealth flexibilities for prescribing certain controlled substances, including ADHD stimulants, through December 31, 2025. Here’s what that meant, where things stand in March 2026, and how patients can avoid treatment disruptions.
-
ADHD Medications and Telehealth in 2026: What the Extended Federal Prescribing Rules Mean for Patients
Federal telehealth flexibilities allowed many ADHD stimulant prescriptions to be written without an in-person exam through December 31, 2025. Here’s what changed, where things stand in March 2026, and how patients can avoid treatment disruptions.
-
What to Know About Medicare Drug Costs in 2026: Caps, Changes, and What They Mean for You
Medicare drug coverage has changed in recent years, including a $2,000 annual cap on out-of-pocket Part D costs. Here’s what people with Medicare should understand in 2026 about prescription costs, payment options, and coverage rules.
-
Prescription Safety in 2026: What FDA Warnings and Ongoing Drug Shortages Mean for Patients
Recent FDA safety communications about compounded medications and ongoing drug supply shifts are raising new questions for patients. Here’s what to know about prescription safety, shortages, and how to protect yourself.
-
Understanding Drug Recalls in the U.S.: What They Mean and What to Do
Drug recalls can sound alarming, but not all recalls carry the same level of risk. Here’s how the FDA’s recall system works, what different classifications mean, and what patients should do if a medication they use is recalled.
-
Antibiotics and Dental Care: What Patients Should Know About Resistance and Safe Use
Dentists prescribe millions of antibiotics each year. Here’s what the latest public health guidance says about when they’re needed, when they’re not, and why it matters for your health.
-
Drug Recalls in the United States: What They Mean and What to Do If You’re Affected
Drug recalls can be confusing and concerning. Here’s how the FDA handles recalls in the U.S., what different recall classes mean, and what patients and families should do if a medication they use is recalled.
-
Prescription Drug Shortages in the U.S.: What Patients Should Know in 2026
Prescription drug shortages continue to affect patients across the United States. Here’s what the FDA says, why shortages happen, and practical steps you can take if your medication is hard to find.
-
ACE Inhibitors: What to Know About These Common Blood Pressure Medications
ACE inhibitors are widely used in the United States to treat high blood pressure, heart failure, and kidney disease. Here’s what they do, who benefits, possible side effects, and what patients and families should understand.
-
Acebutolol: What to Know About This Beta Blocker for Heart Rhythm and Blood Pressure
Acebutolol is a prescription beta blocker used to treat high blood pressure and certain heart rhythm disorders. Here’s how it works, who may benefit, common side effects, and what U.S. patients should know about safety and monitoring.
End of content
End of content
